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KESAN EKSTRAK EURYCOMA LONGIFOLIA DAN EURIKOMANON 
PADA STEROIDOGENESIS DALAM SEL LEYDIG MENCIT 
 
ABSTRAK 
 
Eurycoma longifolia Jack (Tongkat Ali) adalah salah satu tumbuhan 
tradisional yang paling popular di hutan hujan tropika Asia Tenggara, terutamanya di 
Malaysia dan Indonesia. Walaupun E. longifolia telah digunakan secara meluas 
sebagai perubatan tradisional, hanya sedikit pengetahuan yang difahami tentang 
kesannya terhadap sel-sel Leydig iaitu sel-sel yang menghasilkan testosteron. Oleh itu, 
kesan ekstrak E. longifolia (F2) terpiawai dan sebatian tulennya (eurikomanon, EN) 
terhadap penghasilan testosteron, estrogen dan aromatase dalam sel-sel Leydig tikus 
telah dikaji di mana Formestan (FM) digunakan sebagai kawalan positif dalam kajian 
ini. Kesan F2, EN dan FM terhadap kemandirian sel-sel telah ditentukan terlebih 
dahulu dengan menggunakan ujian MTT. Kitaran sel-sel Leydig yang dirawat 
kemudiannya menjalani pewarnaan dengan Propidium iodide (PI) sebelum dianalisis 
secara Sitometri-Aliran. Tahap testosteron, estrogen dan aromatase dalam sel-sel 
Leydig yang dirawat kemudiannya ditentukan secara ELISA. Akhirnya, aktiviti enzim 
aromatase disaring dengan menggunakan kit saringan rencatan daya pemprosesan 
tinggi. Kajian ini mendapati bahawa kesan rencatan pertumbuhan meningkat secara 
dos-berkeperluan dalam sel Leydig yang dirawat dengan F2. Walau bagaimanapun, 
fenomena ini tidak dilihat dalam sel-sel yang dirawat dengan EN dan FM melainkan 
kepekatan yang tinggi digunakan. Analisis kitaran sel menunjukkan bahawa 
kemandirian sel yang dirawat dengan F2 berkurangan kerana kitaran sel-sel 
terbantut/terhenti pada fasa S pada 96 jam rawatan. Penghentian kitaran sel-sel yang 
jelas pada fasa S juga dapat diperhatikan pada sel-sel yang dirawat dengan EN pada 
xviii 
 
rawatan 24 jam dan 48 jam . Walau bagaimanapun, sel-sel yang terencat telah 
berkurang pada 72 jam dan 96 jam rawatan. Sementara itu, sel-sel yang dirawat FM 
tidak menunjukkan perencatan kitaran sel yang signifikan. ELISA membuktikan 
bahawa sel-sel Leydig yang dirawat dengan F2, EN dan FM meningkatkan paras 
testosteron, mungkin disebabkan oleh pengurangan penukaran testosteron kepada 
estrogen. Penambahan hCG di dalam medium pertumbuhan telah merangsang proses 
ini di mana peningkatan pengumpulan testosteron di dalam medium dapat 
diperhatikan seawal 48 jam rawatan. Hasil lanjut menunjukkan bahawa ekspresi gen 
aromatase telah direncat dalam sel-sel yang dirawat dengan F2 dan FM. Hal ini 
mungkin menyebabkan pengurangan kemandirian sel-sel memandangkan ekspresi 
gen aromatase tidak dipengaruhi oleh sel yang dirawat dengan EN. Hasil kajian 
menunjukkan terdapat perencatan yang jelas apabila EN dan FM digunakan sebagai 
sebatian ujian. Bagaimanapun, F2 tidak menunjukkan sebarang kesan rencatan 
terhadap akitiviti enzim aromatase, oleh itu dapat disimpulkan bahawa ekspresi enzim 
aromatase yang lebih rendah berkemungkinan disebabkan oleh jalur penghasilan 
steroid yang lain seperti enzim 5α-reduktase. Hasil kajian ini telah meningkatkan 
pemahaman bahawa ekstrak piawai E. longifolia, F2 dan sebatian tulen, EN  mungkin 
berguna untuk kajian masa hadapan dalam merawat masalah kesihatan manusia, 
seperti ketidaksuburan. 
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THE EFFECTS OF EURYCOMA LONGIFOLIA EXTRACT AND 
EURYCOMANONE ON THE STEROIDOGENESIS IN  
MOUSE LEYDIG CELLS 
 
ABSTRACT 
 
 Eurycoma longifolia Jack (Tongkat Ali) is one of the most popular traditional 
plants found in the tropical rainforest of Southeast Asia, especially in Malaysia and 
Indonesia. Although E. longifolia is widely used as traditional medicine, little is 
understood of the in vitro effect on Leydig cells; the testosterone-producing cells. 
Therefore, the effect of a standardised E. longifolia extract (F2) and pure compound, 
eurycomanone (EN) on the productions of testosterone, estrogen and aromatase in 
mouse Leydig cells were determined in this study, whereby the Formestane (FM) was 
used as a positive control. The effect of F2, EN and FM on the cell viability was first 
determined using MTT assay. The cell cycle of the treated Leydig cells was then 
subjected to Propidium iodide (PI) staining prior analysed by Flow Cytometry. The 
levels of testosterone, estrogen and aromatase in treated Leydig cells were then 
determined by ELISA. Finally, the aromatase enzyme activity was screened using a 
high throughput inhibitor screening kit. The study found that the growth inhibitory 
effect increased in a dose-dependent manner in the Leydig cells treated with F2. 
However, this phenomenon was not observed in EN- and FM-treated cells despite 
when higher concentrations were used. Cell cycle analysis revealed that F2-treated 
cells reduced viability due to the cell cycle arrest at S phase within 96 hours treatment. 
A significant S phase cell cycle arrest at 24 hours and 48 hours treatments could also 
be observed in EN-treated cells. However, the arrested cells were reduced at 72 hours 
and 96 hours treatments. Meanwhile, FM-treated cells did not show any significant 
xx 
 
cell cycle arrest. The ELISA revealed that F2-, EN- and FM-treated Leydig cells 
increased the level of testosterone may be due to the reduction of the conversion of 
testosterone to estrogen. The hCG supplemented growth medium enhanced this 
process, whereby the increased testosterone accumulation in conditioned medium was 
observed as early as at 48 hours treatment. Further results showed the aromatase gene 
expression was inhibited in the F2- and FM-treated cells. This may be attributed to the 
cell viability reduction as the aromatase gene expression was not affected by the EN 
treatment. The results showed a clear inhibition when EN and FM were used as the 
test compounds. However, F2 did not show any promising inhibitory effect on the 
aromatase enzyme activity, which concludes that the lower aromatase enzyme 
expression might be due to other steroidogenesis pathways, such as by 5α-reductase 
enzyme. The results have contributed to the understanding that the standardized E. 
longifolia extract, F2 and pure compound, EN might be useful for future study in 
treating human health problems, such as infertility. 
 
1 
 
CHAPTER ONE  
INTRODUCTION 
 
1.0 General introduction 
Malaysia is categorized as a mega biodiversity-rich country (Ang, 2004) that 
is blessed with the abundance of valuable herbal plants. Herbal medicine can be 
defined as an alternative approach to anyone who uses these herbaceous remedies to 
treat the sick (Kamboj, 2000). The herbal medicine from local plants has been 
traditionally employed decades ago by our ancestors. This medicine is getting 
worldwide attention due to the neutraceutical values and persistent beneficial role in 
human health (Graham et al., 2000). Apart from that, the medicinal plants are believed 
as safe to use and are not prone to cause dependency or addiction as compared to the 
synthetic drugs (Olaku & White, 2011). 
 
Eurycoma longifolia Jack or locally known as Tongkat Ali is one of the most 
popular herbal plants that have been used extensively in Southeast Asia (Jaganath & 
Ng, 2000). Besides, the plants have also contributed as a complementary and 
alternative herbal therapy medicine in the Western countries. E. longifolia is the most 
well-known herbs for their aphrodisiacs property and the ability to reduce infertility 
or erectile dysfunction (Bhat & Karim, 2010). The root of the plant is very valuable, 
where it is widely used for treating fever, aches and glandular swelling (Darise et al., 
1982). Normally, the old folks boil the chipped roots and take it as a decoction or 
sometimes mix it with honey or dates to reduce the taste of bitterness. Currently, E. 
longifolia are supplied in the form of crude powder, in a capsule mixed with other 
herbs or even as an additive in coffee or tea.  
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Infertility is generally defined as incompetency of a couple to reproduce after 
unprotected sexual intercourse for a year (Prakash, 2007). Infertility is a global issue 
affecting one in ten couples that usually due to the problem of the male partner (Burns 
& Covington, 2006). The main factor leading to male infertility is the lifestyle, which 
includes heavy electronic devices usage, alcohol consumption, horse riding and 
wearing close-fitting attire. Improper diet and a stressful working environment could 
also lead to infertility (Sharpe & Franks, 2002). Currently, many advanced therapeutic 
approaches and technologies are used for treating infertility, such as in vitro 
fertilization (IVF), intra-cytoplasmic sperm injection (ICSI) and hormonal therapy. 
However, these methods are very costly and time-consuming, which eventually leads 
to socio-economic problems because not everyone can afford it (Katz et al., 2002). 
Hence, the studies on herbal medicines, such as E. longifolia that is able to increase 
the testosterone level, and hence improve male sexual libido have been done 
extensively. This is to increase the consumption of the herbs through scientific proofs 
and to overcome the current problem, as well as to reduce male infertility. 
 
In this study, a standardised E. longifolia extract (F2) was used in order to 
investigate the effects of the plant as a testosterone booster, and hence combating male 
infertility problem. The effects of the extract were then compared with the pure E. 
longifolia compound; eurycomanone (EN) and a known aromatase inhibitor; 
formestane (FM). The standardised extract F2 consists of four major compounds, 
which includes eurycomanone (EN), 13α (21)-epoxyeurycomanone (EP) and 13, 21-
dihydroeurycomanone (DHY) and eurycomanol (EL). These methanolic root extracts 
of E. longifolia, F2 and EN were provided by Prof. Dr. Chan Kit Lam from the School 
of Pharmaceutical Sciences, USM. The investigation of the effects of F2 and EN was 
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carried out as below. Firstly, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay was done to identify the cytotoxic effect of F2 and EN on the 
primary testosterone producing cell, the Leydig cell (TM3). Next, the cell cycle 
analysis was done using Flow Cytometry to detect the phases of arrested Leydig cells 
in the cell cycle post-treatment with F2 and EN. 
 
Moving to the levels of testosterone and estrogen released from the F2 and EN-
treated Leydig cell into the conditioned media, the investigation was checked using 
enzyme-linked immunosorbent assay (ELISA). Human chorionic gonadotropin (hCG) 
was incorporated into the treatment media during treatments as it mimics the role of 
Luteinizing hormone (LH), which triggers the Leydig cells to secretes testosterone 
(Chen et al., 1994). The expression level of aromatase that is responsible for 
converting testosterone to estrogen in the F2 and EN-treated Leydig cells was also 
observed using ELISA. Finally, the aromatase inhibition activity was detected by 
screening the effect of F2, in comparison to EN and FM using CYP19/MFC high 
throughput inhibitor screening kit.  
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1.1 Problem Statement  
Enhanced testosterone level and spermatogenetic effect by E. longifolia are 
mainly due to the presence of quassinoids in the plant extracts (Talbott et al., 2013). 
Quassinoid is a biological compound that contributes to E. longifolia as the 
testosterone production booster, whereby the extracts enriched by quassinoid in E. 
longifolia is more effective as the booster. The effects of E. longifolia extracts have 
been determined in the animal model previously. However, despite the preliminary 
effect of quassinoid-rich E. longifolia was determined in the rat interstitial cells (Low 
et al., 2013a), the in vitro effects of E. longifolia extracts have not been investigated 
at the molecular level in depth previously especially using Leydig cells. Therefore, it 
is important to determine the effects of the extract isolated from E. longifolia root, F2, 
in comparison of the effects with the pure E. longifolia compound (EN) and the 
aromatase inhibitor (FM) using mouse Leydig cells. It is crucial to investigate the 
mechanisms and actions of the extract to further identify the potency of E. longifolia 
for human use. 
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1.2 Objectives 
 This study aimed to determine the in vitro effects of extracts from the root of 
E. longifolia, F2 and EN using mouse Leydig cells. The specific objectives of this 
study are: 
1. To determine the inhibitory effects of F2 and EN on the viability of Leydig cell 
using MTT assay. 
2. To detect the phases of the cell cycle that were arrested in the Leydig cells post F2 
and EN treatment using flow cytometry. 
3. To investigate the effects of F2 and EN on the production of testosterone and 
estrogen, as well as the expression of aromatase in Leydig cells using ELISA.  
4. To study the potential of F2 and EN on the aromatase activity inhibition using an 
inhibitor screening kit. 
The aromatase inhibitor (FM) were used as the controls for the investigation. The 
effects of F2 and EN were then compared with FM in Leydig cells in this study. 
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CHAPTER TWO  
LITERATURE REVIEW 
 
2.1 The Eurycoma longifolia Jack 
2.1.1 The characteristics of E. longifolia  
Eurycoma longifolia Jack is a plant belongs to the family Simaroubaceae. The 
plant is widely known as ‘Tongkat Ali’ in Malaysia, ‘Pasakbumi’ in Indonesia, ‘Cay 
ba binh’ in Vietnam and ‘Ian-don’ in Thailand (Meng et al., 2014). According to Puri 
(2011), the Genus Eurycoma consists of almost 200 species as a whole. The plants are 
found in tropical rainforests throughout Southeast Asia especially in Malaysia and 
Indonesia. The plants can also be found in Thailand, Vietnam, Laos and Philippines 
to a lesser extent. E. longifolia is well known as Malaysian ginseng (Zanoli et al., 
2009) or national treasure (Mohamed et al., 2015) and hence it is the focus of our 
present study. 
 
E. longifolia is a slow growing, an evergreen herbal tree that is able to grow in 
poor nutrients soil, but better in proper shades and sunlight. According to Puri (2011), 
the plant grows slender up until 12-15 m high (Figure 2.1). E. longifolia bears green 
coloured ovoid fruits, which will gradually turn to dark red upon ripening after 2-3 
years of cultivation. The complete maturation of this plant may take up to 25 years, 
however, the roots are mostly harvested after 4 years of cultivation for commercial 
purposes. The leaves are roughly 5-20 cm long, pinnated and spirally arranged. Each 
leaves consist of numerous obovate-lanceolate leaflets. This dioecious plant born male 
and female flowers on different trees (Bhat & Karim, 2010). The reddish flowers are 
tiny and densely arranged. Harvesting of Tongkat Ali is highly restricted since they 
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have been declared as a protected plant in Malaysia. Currently, E. longifolia root 
extracts are commercialized by mixing them with tea, coffee and carbonated beverages 
as an alternative to improve general health.  
 
 
 
Figure 2.1: The E. longifolia tree is growing rapidly in the natural habitat at the 
main campus of Universiti Sains Malaysia (Bhat & Karim, 2010). 
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2.1.2 The compounds isolated from E. longifolia extract 
The effectiveness of E. longifolia is mainly due to the presence of various 
bioactive constituents in the roots, stems, leaves and even bark of the plant. The plant 
mainly contains quassinoids, quassinoid diterpenoids, tirucallene-type triterpenes, 
squalene derivatives, biphenylneolignans, anthraquinones, canthinone alkaloids and 
dimeric dihydrobenzofuran (Teh et al., 2010). Quassinoids, the most common 
bioactive compounds found indigenously in the plant are naturally occurring degraded 
triterpenes. 
  
Four quassinoids; pasakbumin-A, -B, -C, and -D from E. longifolia were 
separated and identified by Tada et al. (1991). The authors eventually found that 
pasakbumin-A (eurycomanone) and pasakbumin-B are actually responsible for 
exhibiting potent anti-ulcer activity. A few quassinoids were isolated from the leaves 
of E. longifolia, which includes lonilactone, 6-dehydrolonilactone, 11-
dehydroklaineanone, 12-epi-dehydroklaineanone, 15β-hydroxyklaineanone, 14,15β-
dihydroxyklaineanone, and 15-β-O-acetyl-14-hydroxyklaineanone (Jiwajinda et al., 
2001). These compounds were reported to possess anti-tumor effects and anti-parasitic 
activities.  
 
Kuo et al. (2004) reported the isolation of nearly 65 compounds from the roots 
of E. longifolia. The structures of the compounds have also been determined by 
extensive spectroscopic methods, including one-dimensional (1-D) and two-
dimensional nuclear magnetic resonance spectroscopy (2-D NMR), apart from mass 
spectral data. For the first time, the authors identified 4 quassinoids diterpenoids 
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obtained from natural sources, which includes eurycomalideA, eurycomalide B, 5α-
14β, 15β-trihydroxyklaineanone and 13β, 21-dihydroxyeurycomanol.  
 
Park et al. (2014) identified 5 new quassinoids; eurylactone E, eurylactone F, 
eurylactone G, eurycomalide D and eurycomalide E together with 10 known 
quassinoids, which were isolated from the roots of E. longifolia and characterized the 
compounds as above approaches. 
 
Rehman et al. (2016) classified the different type of quassinoids based on their 
number of carbon atoms forming their basic skeleton (C18, C19 and C20). 
Laurycolactone A, laurycolactone B, eurycolactone B and eurycolactone D are 
categorized as C18. On the other hand, 6α-hydroxyeurycomalactone, 7α-
hydroxyeurycomalactone, eurycomalide A and eurycolactone E are a few examples of 
quassinoids under the C19 category. These C-19 quassinoids portrays a wide range of 
biological activities, such as anti-plasmodial, anti-malarial, anti-leukemic, anti-
tubercular and anti-viral. Finally, C20 quassinoids are the largest extent and gaining 
serious attention. They include eurycomanone, eurycomanol and 13α (21)-
dihydroeurycomanone. 
 
Using the wood of E. longifolia, Morita et al. (1992) isolated different biphenyl 
neolignans. This includes the novel isomeric 2,2’-dimethoxy-4’-(-3-hydroxy-1-
propenyl)-4-(1,2,3-trihydroxypropyl) diphenyl ethers and another 2 novel biphenyls, 
2-hydroxy-3,2’,6’-trimethoxy-4’-(2,3-epoxy-1-hydroxypropyl)-5-(3-hydroxy-1-
propenyl)biphenyl and 2-hydroxy-3,2’-dimethoxy-4’-(2,3-epoxy-1-hydroxypropyl)-
5-(3-hydroxy-1-propenyl)biphenyl. 
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Meanwhile, an isolation of 5 new canthin-6-one alkaloids were done by 
Mitsunaga et al. (1994) from the bark and wood of E. longifolia. The isolated 
compounds includes, 10-hydroxy-9-methoxycanthin-6-one, 11-hydroxy-10-
methoxycanthin-6-one, 5,9-dimethoxycanthin-6-one and 9-methoxy-3-
methylcanthin-5,6-dione, 9,10-dimethoxycanthin-6-one. 
 
2.1.3 The aphrodisiacs and anti-infertility activities of E. longifolia 
The plant is widely used as traditional medicine to treat various diseases in 
South-East Asia, and has been scientifically proven to possess medicinal and healing 
properties especially in enhancing sexual prowess. A research was conducted by Ang 
& Sim (1998) for evaluating the effects of E. longifolia root extracts on sexually naive 
male rats. In the process, different fractions of extracts (chloroform, water, butanol) 
were orally administered at different doses (200 mg/kg, 400 mg/kg and 800 mg/kg 
body weight). The authors revealed that the sexual performance of the treated animals 
increased in a dose-dependent manner. Besides, an improvement in mounting, 
intromission and ejaculation were also reported evidencing E. longifolia as a potential 
sexual stimulator. 
 
The administration of different E. longifolia fractions on middle-aged male rats 
changes their sexual behaviour (orientation activities) towards receptive females. The 
changes includes anogenital sniffing, licking and mounting apart from an increment 
in genital grooming towards themselves. However, a reduced attraction towards the 
external environment, inclusive of climbing and raring was also observed (Ang & Lee, 
2002). By using sexually stagnant old male rats, the effects of E. longifolia various 
fractions of extracts (methanol, butanol l, chloroform and water) were tested by Ang 
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et al. (2004). The tests were done on the rat’s sexual arousal by observing the act of 
yawning and stretching. The result revealed an increase in yawning and stretching 
especially when the highest dose of extract (800 mg/kg) was used.  
 
An in vivo study was conducted by Chan et al. (2009), to investigate the 
efficacy of E. longifolia standardized methanol extract with major quassinoid contents, 
13α, 21-epoxyeurycomanone, 13α, 21-dihydroeurycomanone, eurycomanone and 
eurycomanol on infertile rats. The authors concluded that there was a significant 
increase in sperm count, morphology and plasma testosterone level in a dose 
dependent-manner. The results suggest that E. longifolia is crucial to enhance male 
fertility.  
 
Since most of the study conducted on E. longifolia focused on rodents, Tambi 
& Imran (2009) used the standardized, water-soluble E. longifolia root extract on 
humans. The study investigated the semen volumes, sperm concentration, normal 
sperm morphology percentage and sperm motility of 75 sub-fertile male patients after 
given 200 mg of E. longifolia water extract daily for 3 months. An improvement in all 
of the semen parameters was observed, including the sperm quality, which allows 
14.7% of spontaneous pregnancy. A total of 76 patients with late-onset hypogonadism 
were administered with 200 mg of a standardised water-soluble E. longifolia extract 
for 1 month. After the test period, the patients showed improved sign of ageing male 
symptoms and apparently, even the serum testosterone level increased (Tambi et al., 
2012). 
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Low et al. (2013a) carried out an investigation on the effects of standardized 
E. longifolia bioactive fraction and its chemical contents on male fertility and the 
involved mechanism of action. The finding revealed that the sperm concentration of 
the male rats administered with E. longifolia extract was increased. Apart from that, 
the authors observed an elevation of the spermatocytes number, round spermatids and 
Leydig cells as compared to the control. When treated with 25 mg/kg of the extract, 
the rat’s testicular testosterone hiked up while the estrogen level was significantly 
lower. It was also concluded that quassinoids (eurycomanone and 13α, 21-
dihydroeurycomanone) increased the testosterone level of Leydig cells. 
 
A recent study by Ebrahimi et al. (2016) observed the effectiveness of different 
quassinoid levels in E. longifolia extract on rats sperm count. The urinary metabolic 
changes post-treatment was evaluated as well. In the process, 24 male Sprague-
Dawley rats were orally administered with different concentrations of extracts at the 
duration of 48 days. Post-treatment, NMR analysis of the urine samples was done and 
the sperm count was analysed. The result showed that rats given quassinoid-rich 
extract have higher sperm concentration compared to rats given the quassinoid-poor 
aqueous extract. 
 
 Apart from treating male infertility, Abdul-Ghani et al. (2012) proved that E. 
longifolia extract can also be used to treat female sexual disorders. The effect of E. 
longifolia extract on two reproductive disorders in female rats, which were the ovarian 
cystic follicles and irregular estrous cycle, were examined by first treating the rats with 
a hormone that is responsible in inducing reproductive disorder. Post-treatment, the 
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result clearly showed a reversal effect where the number of rats showed the disorder 
was reduced. 
 
2.1.4 Anti-malarial and anti-cancer properties of E. longifolia 
 Malaria is well-known as one of the most deadly diseases in the world with 
over 2 million death per year. Moreover, the infesting Plasmodium falciparum has 
developed a resistance against chloroquine treatment, which has been extensively used 
previously (Miller et al., 1986). Therefore, an alternative research was taken using E. 
longifolia extracts considering the problem. Using E. longifolia that is traditionally 
used as medicine in Vietnam, Nguyen-Pouplin et al. (2007) and Le et al. (2003), the 
studies discovered that the extract portrayed a high anti-malarial activity and the 
potential to inhibit the growth of chloroquine-resistant P. falciparum.  
 
Besides, a study was conducted by Chan et al. (1986) to test the efficacy of E. 
longifolia extract on anti-plasmodial activity against K-1, a Thailand strain multi-drug 
resistant to P. falciparum. The study was carried out under in vitro condition and the 
isolation of 10-hydroxycanthin-6-one, eurycomalactone, eurycomanone and 
eurycomanol from the plant showed anti-malarial activity. Replacing the culture 
medium containing quassinoids-rich E. longifolia extract daily against 6 isolates of P. 
falciparum revealed a complete inhibition as early as 3 days post-treatment (Ang et 
al., 1995). By using in vivo method, Mohd et al. (2007) evaluated the anti-malarial 
property of E. longifolia root standardized extract (TA164), and revealed that the 
TA164 combined with artemisinin repressed the Plasmodium yoelii infection in the 
experimental mice. 
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 On the other hand, cancer is also another leading disease that causes death day 
by day; more cases are being reported every day. Plant-derived cancer medicine should 
be cytotoxic towards cancer cells, which will eventually cause cancer cell death 
(Rehman et al., 2016) and mild adverse effect on healthy cells. Eurylene, a new 
squalene-type triterpene that was isolated from E. longifolia by Itokawa et al. (1991), 
was found toxic towards cancer cells. In another study, Okano et al. (1995) 
investigated the anti-cancer promoting activity of quassinoids and revealed more than 
50% inhibitory effect through a methylenedioxy bridge with a side chain enhancing 
the activity. On the other hand, Chuen & Azimahtol (2004) identified that semi-
purified eurycomanone expressed cytotoxic activity towards MCF-7 breast cancer 
cells. Another study by Nurhanan et al. (2005) used the different type of extracts 
(methanol, n-butanol, chloroform and water) to identify their effects against various 
cancer cells. Eventually, the extracts were cytotoxic towards all of the cell lines, 
excluding a normal MDBK kidney cell line.  
 
2.1.5 The common benefits of E. longifolia 
The root, bark and stem of E. longifolia are used as traditional medicine locally 
(Meng et al., 2014). All parts of this plant particularly the roots have been extensively 
used since a long time to treat different illness, such as fever, intestinal worms, mouth 
ulcers and headache (Perry & Metzger, 1980). The roots of the plant are also used by 
older individuals as traditional ‘anti-aging’ remedy to improve the energy, mood and 
libido reduction problems that often comes with age (Zhari et al., 1999; Hassan et al., 
2012). The roots of E. longifolia also benefits as the herbal ingredient for women after 
childbirth in a way to enhance blood flow and functions (Ismail et al., 1999). Besides, 
the leaves of this plant is used traditionally in curing ulcers, preventing gum diseases 
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and to treat sexually transmitted infections, such as syphilis and gonorrhoea (Bhat & 
Karim, 2010). E. longifolia also served as a health tonic and anti-stress medication 
(Zanoli et al., 2009). Additionally, the plant extracts are widely used as local 
traditional medicines for antipyretic and anti-ulcer (Park et al., 2014). Some of the 
constituents of E. longifolia have also been proven to possess anti-amoebic property 
(Le & Nguyen, 1970). On the other hand, the anti-diabetic property of E. longifolia 
aqueous extract has been proven by Husen et al. (2004). In the treatment of 
osteoporosis, E. longifolia enhanced the testosterone level apart from stimulating the 
proliferation of osteoblast and apoptosis of osteoclast. This phenomenon eventually 
maintained the bone remodelling activity and reduce the risk of bone loss (Mohd et 
al., 2012). 
 
2.1.6 Mechanism and action of E. longifolia  
Numerous studies have been undertaken in order to identify the potential 
valuable effects and biological activities of E. longifolia. However, only a few works 
of literatures recorded the mechanisms and actions of this plant. Table 2.1 summarizes 
some of the identified mechanisms behind the positive effects of E. longifolia. 
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Table 2.1: The mechanism and action of E. longifolia on human health problems and 
diseases. However, no information on the anti-malarial, anti-microbial and anti-
diabetic activities was reported for this extract. 
Effects References Mechanisms 
Anti-tumor Tong et al., 
2015 
Standardised E. Longifolia extract, SQ40, inhibited 
LNCaP cell development by suppressing the 
growth via G0/G1 phase arrest, and accompanied 
by the down-regulation of CDK2, CDK4, Cyclin 
D1 and Cyclin D3, but up-regulation of the protein 
level of p21Waf1/Cip1. 
 Al-Salahi et 
al., 2014 
The TAF273 from E. longifolia root methanolic 
extract showed a potent cytotoxic effect on K-562 
cells via G1 and S phases of cell cycle arrest.  
 Hajjouli et 
al., 2014 
Eurycomanone and eurycomanol of E. longifolia 
inhibited the viability of Jurkat and K-562 cells 
with no effects to the healthy cells. Eurycomanone 
inhibited NF-κB signalling through inhibition of 
IκBα phosphorylation and mitogen-activated 
protein kinase (MAPK) activation. 
 Wong et al., 
2012 
Eurycomanone treatment on lung A549 cancer 
cells decreased the expression of lung cancer 
markers: heterogeneous nuclear ribonucleoprotein 
(hnRNP) A2/B1, p53 tumor suppressor protein and 
other cancer-associated genes, e.g. annexin 1 
(ANX1), prohibitin (PHB) and endoplasmic 
reticulum protein 28 (ERp28). The mRNA 
expression of the studied genes was significantly 
down-regulated except PHB. 
 Zakaria et 
al., 2009 
Eurycomanone possessed anti-cancer effect against 
HepG2 cells by apoptosis induction via the up-
regulation of p53 and Bax, and down-regulation of 
Bcl-2, which increased the levels of cytochrome C. 
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 Tee & 
Azimahtol, 
2005 
Purified extract of E. Longifolia, F16 induced 
apoptosis of MCF-7 via the modulation of Bcl-2 
protein level. 
Anti-
infertility 
Chen et al., 
2015 
E. Longifolia extract improved infertility via 
suppression of α-2-HS glycoprotein expression that 
enhanced the testosterone level and insulin 
sensitivity.  
Anti-
proliferative 
Ohishi et al., 
2015 
9-hydroxycanthin-6-one, a compound extracted 
from E. Longifolia root reduced the expression of 
Wnt signal targeted genes; mitf and zic2a, in 
zebrafish embryos via the activation of GSK3β 
independent CK1α expression. 
Anti-
inflammatory 
Nguyen et 
al., 2015 
7-MCPA (7-methoxy-(9H-β-carbolin-1-yl)-(E)-1-
propenoic acid) isolated from E. longifolia hairy-
root cultures activated Nrf2 through ROS-
dependent p38 MAPK pathway and enhanced the 
activation of the Nrf2/HO-1 pathway which 
showed anti-inflammatory effect. 
Anti-
osteoporosis 
Shuid et al., 
2012 
E. Longifolia extract supplementation on male 
Sprague-Dawley rats elevated the testosterone 
level. The supplement also reduced the bone 
resorption marker and up-regulated OPG gene 
expression of the orchidectomised rats, which plays 
important role in the the protective effects of E. 
Longifolia extract against bone resorption due to 
androgen deficiency. 
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2.2 The Leydig cells 
Leydig cells were first discovered by a German scientist named Franz Leydig 
in 1850, and hence the cells are named after him (Mendis-Handagama & Ariyaratne, 
2005). Leydig cells are the cells that are located in the interstitial compartment of the 
testis, adjacent to the seminiferous tubules (Figure 2.2) and they are the sole source of 
androgens from the testis (Dong & Hardy, 2004). Generally, Leydig cells are 
morphologically epitheloid and ovoid with the presence of different organelles, such 
as cytoplasm, euchromatic round eccentric nuclei, nucleolus and mitochondria. There 
are two major types of Leydig cells; fetal Leydig cells and adult Leydig cells 
(Svechnikov et al., 2010). 
 
During embryogenesis, fetal Leydig cells emerge and develop in the uterus. 
(Benton, 1995). Upon developing, the cell becomes terminally differentiated and 
competently produce testosterone before birth occurs (Shima et al., 2013). The 
testosterone released by fetal Leydig cells is very crucial for male reproductive system 
differentiation, especially for testis in gestation (Huhtaniemi & Pelliniemi, 1992). The 
development process of the cells is independent of Luteinizing hormone (LH) even 
though the cells express LH receptor and respond to LH stimulation (Zhang et al., 
2001). 
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(a) 
 
(b) 
 
Figure 2.2: The Leydig cells. (a) Cross section of a rat testis showing interstitial 
tissue with Leydig cells. (b) The area of interstitial tissue shows a moderate size of 
Leydig cells between the seminiferous tubules (Christensen & Peacock, 1980). 
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On the other hand, adult Leydig cells developed upon puberty from the 
testicular mesenchymal-like stem cells (Ye et al., 2017). The adult Leydig cells 
constantly supply testosterone, which is important for the spermatogenesis process, 
sex gland accessories development and also the emergence of secondary sexual 
characteristics (Svechnikov et al., 2010). The adult Leydig cells continuously form 
with 4 distinct types of identified cells; stem, progenitor, immature and adult (Chen et 
al., 2009). The development of Leydig cells is shown in Figure 2.3. 
 
After 7 days of birth, a spindle-shaped cell, known as stem Leydig cells (SLC) 
could be seen in the testis interstitial space (Ge et al., 2006). However, these cells are 
not under the lineage of Leydig cell since they do not express any of the Leydig-cell 
certain markers, such as LH receptor. A spindle-shaped population of progenitor 
Leydig cells (PLC) developed by 14 days of postnatal. PLC is recognized as Leydig 
cell lineage by expressing LH receptor and also by producing the low level of 
androgen (Shan et al., 1993). PLC has the low abundance of smooth endoplasmic 
reticulum (SER), where steroidogenic enzymes are located. At 28 days of birth, the 
PLC gradually converts from spindle-shaped to round-shaped immature Leydig cells 
(ILC) forming approximately 13-14 million cells (Hardy et al., 1989). The SER of ILC 
expands greatly and they have the intermediate capacity of steroidogenesis (Zirkin & 
Ewing, 1987). From postnatal day 28 to day 56, the adult Leydig cells (ALC), which 
are also round with small lipid droplets, undergo one time doubling process forming 
approximately 25 million cells per testis. The SER is the most abundant at this stage 
and the cells secrete the highest level of testosterone. Normally, ALC does not undergo 
proliferation however, the cells are regenerated once their population is diminished 
(Keeney et al., 1988). 
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Figure 2.3: The development of Leydig cells; (a) stem Leydig cells, (b) immature 
Leydig cells, (c) progenitor Leydig cells, and (d) adult Leydig cells (Chen et al., 
2009).   
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22 
 
2.3 The hypothalamic-pituitary-gonadal axis 
 Leydig cells are able to carry out their primary function, which is testosterone 
secretion through hypothalamic-pituitary-gonadal axis (Erasmus et al., 2012). There 
are three major organs comprising the axis; the hypothalamus, the anterior pituitary 
gland and the testes (Figure 2.4).  
 
 The hypothalamus located in the brain first produces and secretes 
Gonadotropin-releasing hormone (GnRH) in a pulsatile manner. GnRH then triggers 
the release of Luteinizing hormones (LH) and Follicle stimulating hormones (FSH) in 
the anterior pituitary gland. LH and FSH are the two gonadotropic hormones released 
by both males and females. They share a common α-peptide chain with human 
chorionic gonadotrophin (hCG), but differs from each other by a specific β-peptide 
chain, which specifies their biological action (Gingrich, 2010).  
 
 The FSH functions on Sertoli cells, where the spermatogenesis process occurs, 
and is stimulated by the release of androgen-binding protein (ABP). This ABP bind 
with testosterone produced outside of the seminiferous tubules in order to maintain the 
growth of germ cells (Prante et al., 2008). Meanwhile, in the testis, LH stimulates the 
Leydig cells to secrete testosterone. When the testosterone level is more than needed, 
the Sertoli cells secrete inhibin that terminates the hypothalamus in releasing GnRH 
in a negative feedback. Therefore, the system is kept in equilibrium (Erasmus et al., 
2012).  
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Figure 2.4: Diagrammatic illustration of the hypothalamic-pituitary-gonadal axis. 
Modified from (Gingrich, 2010). 
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2.4 Steroidogenesis 
 Steroidogenesis is the process of steroid hormones synthesis from the different 
part of human bodies, such as adrenal cortex, testis, ovaries and adipose tissue. 
Example of steroid hormones includes glucocorticoids, mineralocorticoids, androgens 
and estrogens. The biosynthesis of steroid is a series of the complex process with 
consecutive steps. Basically, all steroid hormones are derived from cholesterol 
synthesized by various tissues especially adrenal gland and gonads as their parent 
compound. Steroidogenic acute regulatory protein (StAR) is responsible for 
transporting cholesterol into the mitochondria (Hauet et al., 2006). Several 
steroidogenic enzymes are responsible for the steroid biosynthesis as shown in Table 
2.2. These enzymes are mostly found in the inner mitochondria and smooth 
endoplasmic reticulum. 
 
The steroidogenesis pathway of rodents differ slightly from humans in the 
production of androstenedione (Engeli et al., 2018). In humans, the cholesterol is first 
converted to pregnenolone by a cholesterol side-chain cleavage enzyme, CYP11A 
(Parker & Schimmer, 1995). The pregnenolone is then converted to 17-hydroxy 
pregnenolone and further down to dehydroepiandrosterone (DHEA) by the CYP17 
enzyme. An enzyme that is known as 3β-hydroxysteroid dehydrogenase then converts 
DHEA to an androgen, androstenedione. In contrast, rodents prefer intermediate 
progesterone and 17-hydroxy progesterone enzyme for androstenedione conversion. 
This androstenedione is a weak androgen, which is converted to testosterone by 17β-
hydroxysteroid dehydrogenase (17β-HSD) in both humans and rodents. The 17β-HSD 
types 3 and 5 are responsible to catalyse the conversion of androstenedione to 
testosterone, which is expressed in testis Leydig cells (Mindnich et al., 2004). Finally, 
